Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
Clinical trial NCT05791097 · WITHDRAWN
Trial details
- NCT number
- NCT05791097
- Sponsor
- Novartis Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-28
- Primary completion
- 2027-12-24
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.